Two children with Guillain-Barrè syndrome were succesfully treated with high-dose intravenous immunoglobulin (IVIG) and no relapses occurred over a 1 year follow up. No side-effects were observed. These data provide further evidence that IVIG may be safely and effectively employed in children with Guillain-Barrè syndrome.
- Guillain-Barrè syndrome
- Intravenous immunoglobulin
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health